Immunogenetics

, Volume 59, Issue 6, pp 511–515 | Cite as

Wild type and H43Y variant of human TRIM5α show similar anti-human immunodeficiency virus type 1 activity both in vivo and in vitro

  • Emi E. Nakayama
  • Wassila Carpentier
  • Dominique Costagliola
  • Tatsuo Shioda
  • Aikichi Iwamoto
  • Patrice Debre
  • Kazuhisa Yoshimura
  • Brigitte Autran
  • Shuzo Matsushita
  • Ioannis Theodorou
Brief Communication

Abstract

Polymorphisms in human genes have been shown to affect the rate of disease progression to acquired immune deficiency syndrome in human immunodeficiency virus type 1 (HIV-1)-infected individuals. Recently, tripartite motif 5α (TRIM5α) was identified as a factor that confers resistance to HIV-1 infection in Old World monkey cells. Subsequently, Sawyer et al. (Curr Biol 16:95–100, 2006) reported a single nucleotide polymorphism (H43Y) in the human TRIM5α gene and TRIM5α protein with 43Y was found to lose its ability to restrict HIV-1. In the present study, we reevaluated effects of this allele on in vitro anti-HIV-1 activity as well as on HIV-1 disease progression in European and Asian cohorts of HIV-1-infected individuals. Our epidemiological and molecular biological findings clearly indicate H43Y has a very minor effect on anti-HIV-1 activity of TRIM5α, suggesting that this allele is immaterial, at least in HIV-1-infected Europeans and Asians.

Keywords

TRIM5α H43Y RING domain Polymorphism HIV-1 disease progression Anti-HIV-1 activity 

References

  1. Goldschmidt V, Bleiber G, May M, Martinez R, Ortiz M, Telenti A (2006) Role of common human TRIM5alpha variants in HIV-1 disease progression. Retrovirology 3:54PubMedCrossRefGoogle Scholar
  2. Hatziioannou T, Perez-Caballero D, Yang A, Cowan S, Bieniasz PD (2004) Retrovirus resistance factors Ref1 and Lv1 are species-specific variants of TRIM5alpha. Proc Natl Acad Sci USA 101:10774–10779PubMedCrossRefGoogle Scholar
  3. Javanbakht H, An P, Gold B, Petersen DC, O’Huigin C, Nelson GW, O’Brien SJ, Kirk GD, Detels R, Buchbinder S, Donfield S, Shulenin S, Song B, Perron MJ, Stremlau M, Sodroski J, Dean M, Winkler C (2006) Effects of human TRIM5alpha polymorphisms on antiretroviral function and susceptibility to human immunodeficiency virus infection. Virology 354:15–27PubMedCrossRefGoogle Scholar
  4. Kasper DL, Fauci AS, Longo DL, Braunwald E, Hauser SL, Jameson JL (2005) Harrison’s Principles of Internal Medicine. McGraw-Hill, New YorkGoogle Scholar
  5. Keckesova Z, Ylinen LM, Towers GJ (2004) The human and African green monkey TRIM5alpha genes encode Ref1 and Lv1 retroviral restriction factor activities. Proc Natl Acad Sci USA 101:10780–10785PubMedCrossRefGoogle Scholar
  6. Magierowska M, Theodorou I, Debre P, Sanson F, Autran B, Riviere Y, Charron D, Costagliola D (1999) Combined genotypes of CCR5, CCR2, SDF1, and HLA genes can predict the long-term nonprogressor status in human immunodeficiency virus-1-infected individuals. Blood 93:936–941PubMedGoogle Scholar
  7. Nakayama EE, Miyoshi H, Nagai Y, Shioda T (2005) A specific region of 37 amino acid residues in the SPRY (B30.2) domain of African green monkey TRIM5alpha determines species-specific restriction of simian immunodeficiency virus SIVmac infection. J Virol 79:8870–8877PubMedCrossRefGoogle Scholar
  8. Nakayama EE, Maegawa H, Shioda T (2006) A dominant-negative effect of cynomolgus monkey tripartite motif protein TRIM5alpha on anti-simian immunodeficiency virus SIVmac activity of an African green monkey orthologue. Virology 350:158–163PubMedCrossRefGoogle Scholar
  9. Perez-Caballero D, Hatziioannou T, Yang A, Cowan S, Bieniasz PD (2005) Human tripartite motif 5alpha domains responsible for retrovirus restriction activity and specificity. J Virol 79:8969–8978PubMedCrossRefGoogle Scholar
  10. Perron MJ, Stremlau M, Song B, Ulm W, Mulligan RC, Sodroski J (2004) TRIM5alpha mediates the postentry block to N-tropic murine leukemia viruses in human cells. Proc Natl Acad Sci USA 101:11827–11832PubMedCrossRefGoogle Scholar
  11. Sawyer SL, Wu LI, Emerman M, Malik HS (2005) Positive selection of primate TRIM5alpha identifies a critical species-specific retroviral restriction domain. Proc Natl Acad Sci USA 102:2832–2837PubMedCrossRefGoogle Scholar
  12. Sawyer SL, Wu LI, Akey JM, Emerman M, Malik HS (2006) High-frequency persistence of an impaired allele of the retroviral defense gene TRIM5alpha in humans. Curr Biol 16:95–100PubMedCrossRefGoogle Scholar
  13. Speelmon EC, Livingston-Rosanoff D, Li SS, Vu Q, Bui J, Geraghty DE, Zhao LP, McElrath MJ (2006) Genetic association of the antiviral restriction factor TRIM5alpha with human immunodeficiency virus type 1 infection. J Virol 80:2463–2471PubMedCrossRefGoogle Scholar
  14. Stremlau M, Owens CM, Perron MJ, Kiessling M, Autissier P, Sodroski J (2004) The cytoplasmic body component TRIM5alpha restricts HIV-1 infection in Old World monkeys. Nature 427:848–853PubMedCrossRefGoogle Scholar
  15. Stremlau M, Perron M, Welikala S, Sodroski J (2005) Species-specific variation in the B30.2(SPRY) domain of TRIM5alpha determines the potency of human immunodeficiency virus restriction. J Virol 79:3139–3145PubMedCrossRefGoogle Scholar
  16. Yap MW, Nisole S, Lynch C, Stoye JP (2004) Trim5alpha protein restricts both HIV-1 and murine leukemia virus. Proc Natl Acad Sci USA 101:10786–10791PubMedCrossRefGoogle Scholar
  17. Yap MW, Nisole S, Stoye JP (2005) A single amino acid change in the SPRY domain of human Trim5alpha leads to HIV-1 restriction. Curr Biol 15:73–78PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2007

Authors and Affiliations

  • Emi E. Nakayama
    • 1
  • Wassila Carpentier
    • 2
  • Dominique Costagliola
    • 3
  • Tatsuo Shioda
    • 1
  • Aikichi Iwamoto
    • 4
  • Patrice Debre
    • 2
  • Kazuhisa Yoshimura
    • 5
  • Brigitte Autran
    • 2
  • Shuzo Matsushita
    • 5
  • Ioannis Theodorou
    • 2
  1. 1.Department of Viral Infections, Research Institute for Microbial DiseasesOsaka UniversitySuita-shiJapan
  2. 2.Laboratoire Central d’Immunologie Cellulaire et TissulaireHôpital Pitié Salpetrière et INSERM UR543 Bâtiment CERVIParisFrance
  3. 3.INSERM U 720, Epidemiologie clinique et therapeutique de l’infection a VIHUniversité Pierre et Marie Curie-Paris 6ParisFrance
  4. 4.Division of Infectious Diseases, Institute of Medical ScienceUniversity of TokyoTokyoJapan
  5. 5.Division of Clinical Retrovirology and Infectious Diseases, Center for AIDS ResearchKumamoto UniversityKumamotoJapan

Personalised recommendations